GLP1R and type 2 diabetes mellitus: Pharmacokinetically optimised GLP-1R agonists based on the amino acid sequence of either the cognate agonist GLP-1(7–36)NH2 or its homologue exendin-4 [5] are approved for the treatment of T2D.